Atezolizumab

• CAT Number: I018816
• CAS Number: 1380723-44-3
• Molecular Formula: C6446H9902N1706O1998S42
• Molecular Weight: 144590.59
• Purity: ≥95%
• Target: Apoptosis
• IUPAC Name: (Z)-2-amino-4-[1-(4-amino-3-sulfanylphenyl)but-3-enylimino]-N-butan-2-yl-N-(3-methylpentyl)hept-2-enamide;ethane;(E,3E)-3-ethylidenehex-4-en-2-one
• InChI: 1S/C27H44N4OS.C8H12O.C2H6/c1-7-11-22(30-25(12-8-2)21-13-14-23(28)26(33)17-21)18-24(29)27(32)31(20(6)10-4)16-15-19(5)9-3;1-4-6-8(5-2)7(3)9;1-2/h8,13-14,17-20,25,33H,2,7,9-12,15-16,28-29H2,1,3-6H3;4-6H,1-3H3;1-2H3/b24-18-,30-22?;6-4+,8-5+
• InChIKey: MHXMMWFKILDNLC-OMTIXABGSA-N
• SMILES: CC.CCCC(=NC(CC=C)C1=CC(=C(C=C1)N)S)/C=C(/C(=O)N(CCC(C)CC)C(C)CC)\N.C/C=C/C(=C\C)/C(=O)C

Atezolizumab (Cat No.:I018816) is a selective humanized monoclonal IgG1 antibody developed for cancer research and treatment. It specifically targets programmed death ligand 1 (PD-L1), a protein present on the surface of tumor cells. By binding to PD-L1, atezolizumab blocks the interaction between PD-L1 and programmed death 1 (PD-1) receptors on immune cells, thereby restoring the ability of the immune system to recognize and attack cancer cells. Atezolizumab is used in immunotherapy approaches to treat various types of cancer and has shown promising results in clinical trials.